Bullish Options Surge in Sarepta Therapeutics Amid Promising Rare Disease Data
Traders have flooded Sarepta Therapeutics with call options following positive early-stage data for its RNA-based rare disease therapies. This surge in bullish sentiment suggests high market confidence in the company's clinical pipeline expansion beyond its core Duchenne muscular dystrophy franchise.